Dyne Therapeutics, Inc. financial data

Symbol
DYN on Nasdaq
Industry
Pharmaceutical Preparations
Location
1560 Trapelo Road, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.94K % +214%
Debt-to-equity 8.48 % -73.1%
Return On Equity -49.1 % +64%
Return On Assets -45.2 % +56.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 113M shares +29.5%
Common Stock, Shares, Outstanding 102M shares +66.5%
Entity Public Float 3B USD +495%
Common Stock, Value, Issued 10K USD +66.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 281M USD +33.5%
General and Administrative Expense 62.5M USD +99%
Operating Income (Loss) -344M USD -42%
Net Income (Loss) Attributable to Parent -317M USD -34.5%
Earnings Per Share, Basic -3.37 USD/shares +14.7%
Earnings Per Share, Diluted -3.37 USD/shares +14.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 435M USD +258%
Assets, Current 659M USD +410%
Property, Plant and Equipment, Net 5.4M USD +12.9%
Operating Lease, Right-of-Use Asset 24.6M USD -14%
Assets 691M USD +319%
Accounts Payable, Current 6.56M USD -71.4%
Employee-related Liabilities, Current 13.1M USD +24.7%
Liabilities, Current 42.3M USD -17.3%
Operating Lease, Liability, Noncurrent 19.1M USD -15.7%
Liabilities 61.4M USD -16.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 6K USD
Retained Earnings (Accumulated Deficit) -950M USD -50.2%
Stockholders' Equity Attributable to Parent 630M USD +590%
Liabilities and Equity 691M USD +319%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -78.5M USD -67.4%
Net Cash Provided by (Used in) Financing Activities 408M USD +1317%
Net Cash Provided by (Used in) Investing Activities -180M USD -765%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 102M shares +66.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 150M USD +1573%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 437M USD +253%
Deferred Tax Assets, Valuation Allowance 289M USD +98%
Deferred Tax Assets, Gross 295M USD +94.6%
Operating Lease, Liability 24M USD -12.5%
Payments to Acquire Property, Plant, and Equipment 191K USD -17%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -317M USD -34.9%
Lessee, Operating Lease, Liability, to be Paid 27.9M USD -15%
Property, Plant and Equipment, Gross 12.2M USD +20.9%
Operating Lease, Liability, Current 4.85M USD +2.75%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.13M USD +2.74%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.98M USD +2.77%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.87M USD -27.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.28M USD +2.74%
Deferred Tax Assets, Operating Loss Carryforwards 86.2M USD +50%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.44M USD +2.74%
Additional Paid in Capital 1.58B USD +118%
Depreciation, Depletion and Amortization 1.67M USD 0%
Deferred Tax Assets, Net of Valuation Allowance 6.64M USD +10.4%
Share-based Payment Arrangement, Expense 45.9M USD +130%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%